Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

Lois M. Mulligan, John B. Kwok, Catherine S. Healey et al. · Nature · 1993 · 2K citations

Medicine, Genetics, Molecular Genetics +16

Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

Anita Schuchardt, Vivette D. D’Agati, Lena Larsson-Blomberg et al. · Nature · 1994 · 1.6K citations

Life Sciences, Neurobiology, Neuroscience +14

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

Robert M.W. Hofstra, Rudy M. Landsvater, Isabella Ceccherini et al. · Nature · 1994 · 1.2K citations

Medicine, Genetics, Oncology +16

Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.

Katrin M. Carlson, Shuo‐Xing Dou, N J Scavarda et al. · Proceedings of the National Academy of Sciences · 1994 · 598 citations · Full text

Medicine, Genetics, Oncology +17

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

Medicine, Oncology, Pharmacology +17